Senator Mitt Romney, R-Utah, warned PhRMA that he and his new colleagues are working to tackle the issue of high prescription drug prices; Kentucky is delaying the start of work requirement rules for a portion of its Medicaid population; despite its approval by the FDA last year, Teva’s generic version of an epinephrine autoinjector is not available at the largest pharmacies or through drug distributors.
Senator Mitt Romney, R-Utah, warned the Pharmaceutical Research and Manufacturers of America (PhRMA) that he and his new colleagues are working to tackle the issue of high prescription drug prices in a closed-door meeting, STAT News reported. The industry should be prepared to take part in participate in those discussions, he said.Kentucky is delaying the start of work requirement rules for a portion of its Medicaid population, the Associated Press reported. A federal judge blocked the rules last year, but the Trump administration approved them a second time in November. Some of the rules were to start April 1, but they will now begin no sooner than July 1, the state said.Despite its approval by the FDA last year, Teva’s generic version of an epinephrine autoinjector is not available at the largest pharmacies or through drug distributors, Reuters reported. The short supply means Teva cannot compete with Mylan in a roughly $750 million a year US market. Mylan’s EpiPen has also been in short supply since spring 2018. Teva did not say why its drug was in short supply.
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen